A path to translation: How 3D patient tumor avatars enable next generation precision oncology.
Document Type
Article
Publication Date
12-12-2022
Publication Title
Cancer cell
Keywords
JMG, JGM, Humans, Neoplasms, Precision Medicine, Prospective Studies, Medical Oncology
JAX Source
Cancer Cell. 2022;40(12):1448-53.
Volume
40
Issue
12
First Page
1448
Last Page
1453
ISSN
1878-3686
PMID
36270276
DOI
https://doi.org/10.1016/j.ccell.2022.09.017
Grant
This work was supported by National Cancer Institute grants NIH- U01CA217514 and U01CA214300 as well as National Institutes of Health F30 fellowship 1F30CA257365-01.
Abstract
3D patient tumor avatars (3D-PTAs) hold promise for next-generation precision medicine. Here, we describe the benefits and challenges of 3D-PTA technologies and necessary future steps to realize their potential for clinical decision making. 3D-PTAs require standardization criteria and prospective trials to establish clinical benefits. Innovative trial designs that combine omics and 3D-PTA readouts may lead to more accurate clinical predictors, and an integrated platform that combines diagnostic and therapeutic development will accelerate new treatments for patients with refractory disease.
Recommended Citation
Bose S,
Barroso M,
Chheda M,
Clevers H,
Elez E,
Kaochar S,
Kopetz S,
Li X,
Meric-Bernstam F,
Meyer C,
Mou H,
Naegle K,
Pera M,
Perova Z,
Politi K,
Raphael B,
Robson P,
Sears R,
Tabernero J,
Tuveson D,
Welm A,
Welm B,
Willey C,
Salnikow K,
Chuang J,
Shen X.
A path to translation: How 3D patient tumor avatars enable next generation precision oncology. Cancer Cell. 2022;40(12):1448-53.